TransEnterix (NYSE:TRXC) said today that it won 510(k) clearance from the FDA for a 3mm-diameter instrument set for its Senhance robot-assisted surgery device. The federal safety watchdog also OK’d additional 5mm-diameter instruments, the Research Triangle Park, N.C.-based company said. The 3mm instrument open up micro-laparoscopic “virtually scarless” procedures for Senhance, according to TransEnterix. “The ability to […]
TransEnterix
TransEnterix shares rise on Q3 prelims
Shares in TransEnterix (NYSE:TRXC) rose approximately 5% after the company announced its preliminary third quarter earnings and provided a corporate update on Monday. The Research Triangle Park, N.C.-based company said it expects to post sales of $5.4 million, just in line with the consensus on Wall Street. TransEnterix said that its revenue mainly came through the […]
TransEnterix wins CE Mark for Senhance Ultrasonic instrument package
TransEnterix (NYSE:TRXC) said today that it won CE Mark approval in the European Union for the Senhance Ultrasonic instrument system, designed to operate with its Senhance robot-assisted surgery device. The Research Triangle Park, N.C.-based company said the ultrasound instruments, designed to deliver controlled energy to ligate and divide tissue and minimize thermal injury to surrounding structures, can be […]
TransEnterix puts up $33m for Medical Surgery Technologies
TransEnterix (NYSE:TRXC) said yesterday that it agreed to acquire Medical Surgery Technologies and its surgery planning technology in a two-stage deal worth nearly $33 million. Yokneam, Israel-based MST makes Follow Me, a software package that uses image analytics, advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics to plan robot-assisted surgeries. Follow Me won 510(k) clearance from […]
TransEnterix submits FDA clearance bid for Senhance ultrasonic instrumentation
TransEnterix (NYSE:TRXC) said today it filed an FDA 510(k) submission for its Senhance Ultrasonic instrument system, designed to operate with its Senhance robotic platform. The Research Triangle Park, N.C.-based company said that the approval would allow the system to utilize ultrasonic devices designed to deliver controlled energy to ligate and divide tissue and minimize thermal injury […]
TransEnterix shares fall despite Street-beating Q2
Shares in TransEnterix (NYSE:TRXC) fell today after the robotic surgical platform developer posted second quarter earnings that beat expectations on Wall Street, but showed growing losses. The Research Triangle Park, N.C.-based company posted losses of $34.3 million, or 17¢ per share, on sales of $6.4 million for the three months ended June 30, seeing losses grow […]
TransEnterix jumps on Q2 prelims
TransEnterix (NYSE:TRXC) shares got a jump today when the robot-assisted surgery company released preliminary revenue numbers for the second quarter that outstripped the consensus on Wall Street. Research Triangle Park, N.C.-based TransEnterix said it expects to post sales of $6.0 million to $6.3 million for the three months ended ended June 30, 2018, up 300% to […]
TransEnterix seeks expanded FDA indications for Senhance platform
TransEnterix (NYSE:TRXC) said yesterday it submitted a 510(k) submission to the FDA seeking clearance for extra instruments for its Senhance robotic surgical platform, including 3 mm diameter instruments. The Research Triangle Park, N.C.-based company said that the clearance would allow the Senhance to be used in microlaparoscopic surgeries. The platform is currently cleared for laparoscopic colorectal, […]
TransEnterix surges on expanded indications for Senhance robot-assisted surgery device
TransEnterix (NYSE:TRXC) said today that it won expanded indications from the FDA for its Senhance robot-assisted surgery device, which is now cleared for hernia and gallbladder procedures. The federal safety watchdog’s expanded 510(k) decision doubles the Research Triangle Park, N.C.-based company’s addressable market, president & CEO Todd Pope said in prepared remarks. “These expanded procedures are […]
TransEnterix shares rise on Street-beating Q1
Shares in TransEnterix (NYSE:TRXC) rose today after the medical device maker beat expectations on Wall Street with its first quarter earnings results. The Research Triangle Park, N.C.-based company posted losses of $882,000, or 0¢ per share, on sales of $4.8 million for the three months ended March 31, seeing losses shrink 94.3¢ while sales grew 145% […]
TransEnterix shares dip on Q4, 2017 earnings
Shares in TransEnterix (NYSE:TRXC) have fallen today after the medical device maker posted growing losses in its fourth quarter and full year 2017 earnings. The Research Triangle Park, N.C.-based company posted losses of $76.2 million, or 40¢ per share, on sales of $3.4 million for the three months ended December 31, seeing losses grow 444.3% while […]